Umang Vohra – Global CEO & Managing Director, Cipla
Umang Vohra, managing director and global CEO of Indian pharma giant Cipla, discusses the company’s ambition to grow in both the domestic and emerging markets as well as the opportunities…
Cipla Limited is an Indian multinational pharmaceutical and biotechnology company, headquartered in Mumbai, India. Cipla primarily develops medicines to treat respiratory, cardiovascular disease, arthritis, diabetes, weight control and depression; other medical conditions.
It was founded by Khwaja Abdul Hamied as ‘The Chemical, Industrial & Pharmaceutical Laboratories’ in 1935 in Mumbai. The name of the Company was changed to ‘Cipla Limited’ on 20 July 1984. In the year 1985, US FDA approved the company’s bulk drug manufacturing facilities. Led by the founder’s son Yusuf Hamied, a Cambridge-educated chemist, the company provided generic AIDS and other drugs to treat poor people in the developing world. In 1995, Cipla launched Deferiprone, the world’s first oral iron chelator. In 2001, Cipla offered medicines (antiretrovirals) for HIV treatment at a fractional cost (less than $350 per year per patient).
In 2013 Cipla acquired the South African company Cipla-Medpro, kept it as a subsidiary, and changed its name to Cipla Medpro South Africa Limited. At the time of the acquisition, Cipla-Medpro had been a distribution partner for Cipla and was South Africa’s third-biggest pharmaceutical company. The company had been founded in 2002 and was known as Enaleni Pharmaceuticals Ltd. In 2005, Enaleni bought all the shares of Cipla-Medpro, which had been a joint venture between Cipla and Medpro Pharmaceuticals, a South African generics company, and in 2008 it changed its name to Cipla-Medpro.
Umang Vohra, managing director and global CEO of Indian pharma giant Cipla, discusses the company’s ambition to grow in both the domestic and emerging markets as well as the opportunities…
Anant Atal, head of Latin America for Cipla, discusses how the establishment of offices in Colombia was facilitated by its longstanding history in the country, the multiple initiatives the company…
The Country Head Commercial Business of Cipla Czech Republic reviews the challenges faced since Cipla began Czech operations two years ago, the company’s expertise in the respiratory segment, and how…
As secretary general of the Indian Pharmaceutical Alliance (IPA) Sudarshan Jain represents the interests of 25 leading Indian pharmaceutical companies, both at home and abroad. He outlines the association’s focus…
The IDMA’s Daara Patel outlines the association’s role in representing the diverse voices of the Indian pharmaceutical sector, advocating for manufacturers of all sizes. He explores the challenges and initiatives…
Indian pharma companies have been building a broader presence in LatAm markets over the past two decades. With well-established trade relations already in place, the region offers a series of unique…
A roundup of some of the top stories from the Indian pharma industry including the suspension of the National Medical Commission’s (NMC) guidelines making the prescription of generic drugs mandatory;…
Top stories from Indian pharma including Sanofi India’s plans to demerge its healthcare businesses; Junshi Biosciences and Dr. Reddy’s anti-PD-1 monoclonal antibody partnership; Venus Remedies’ new oncology approvals; CORONA and…
The latest news from the Indian pharma industry, including Dr. Reddy’s purchase of Mayne Pharma’s US portfolio; Sun Pharma’s acquisition of Concert Pharma; Bristol Myers Squibb’s expanded Indian footprint and…
The latest news from the Indian pharma industry, including WHO’s recommendation not to use cough syrup from Marion Biotech after further deaths, Indegene’s expanded presence in Europe, Sun Pharma’s FDA…
The latest news from the Indian pharma sector, including the potential for greater numbers of exports and better market access to the UK under a proposed free trade agreement, yet…
As one of the world’s a leading pharma manufacturers, India supplies about 20 percent of the global pharmaceuticals demand in terms of volume, yet the industry remains plagued with quality…
Top stories from Indian pharma including Dr Reddy’s move to US online platforms, Aspen/Serum Institute’s vaccine deal for Africa, Aurobindo’s USD 37.7 million investment in subsidiary CuraTeQ and Biocon’s FDA…
Arshia Bhandari of patient safety thought leadership forum PhVFIT examines how India is embracing a more patient-centric healthcare model via the implementation of a national patient safety implementation framework. …
The latest healthcare and pharma news from India, including the opening up of COVID-19 vaccine booster shots to all adults; the lowering of vaccine prices; and the licences granted to…
See our Cookie Privacy Policy Here
